A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Pediatric and Adolescent Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ZUMA-4)
Study Evaluating KTE-C19 in Subjects With Acute Lymphoblastic Leukemia or B-Cell Non-Hodgkin Lymphoma (ZUMA-4)
Sponsor: KITE Pharma
Enrolling: Male and Female Patients
Study Length: 15 Years
Clinic Visits: 40
IRB Number: AAAS3695
U.S. Govt. ID: NCT02625480
Contact: Dylan Stein: 212-345-9770 / djs2245@cumc.columbia.edu
Additional Study Information: The main purpose of this research study is to determine if the experimental product, KTE-C19, when administered after you receive 3 days of chemotherapy, is safe and effective in treating your leukemia or non-Hodgkin lymphoma.
This study is closed
Investigator
Prakash Satwani, MD
Do You Qualify?
Do you or your child have leukemia or Non-Hodgkin Lymphoma? Yes No
Do you or your child have measurable disease in the Bone Marrow? Yes No
Is CD19 tumor expression on blasts after your/your child's most recent completion of therapy? Yes No
Do you/ your child have any fungal, bacterial, viral or other infection that is uncontrolled or requiring IV microbials? Yes No
Are you/your child taking corticosteroid therapy at a does of or = to 0.7 mg/kg/day? Yes No
Submit
Cancel
You may be eligible for this study

Place Holder


CAPTCHA
Image CAPTCHA
Enter the characters shown in the image.
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Cancel
For more information, please contact:
Dylan Stein
djs2245@cumc.columbia.edu
212-345-9770
This website uses cookies as well as similar tools and technologies to understand visitors’ experiences. By continuing to use this website, you consent to Columbia University’s usage of cookies and similar technologies, in accordance with the Columbia University Website Cookie Notice.
I AGREE